These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34997835)

  • 41. Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects.
    Sunkara G; Jiang X; Reynolds C; Serra D; Zhang Y; Ligueros-Saylan M; Ayalasomayajula S; Winter S; Jarugula V
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):487-92. PubMed ID: 27129123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioequivalence Evaluation Between Acarbose and Metformin Fixed-Dose Combination and Corresponding Individual Components in Healthy Chinese Male and Female Subjects.
    Liu C; Cleton A; Sui Y; Liu Y; Li J; Yuan F; Sheng L; Xu H; Li X
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):173-184. PubMed ID: 34255938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions.
    Brendel E; Weimann B; Dietrich H; Froede C; Thomas D
    Int J Clin Pharmacol Ther; 2013 Sep; 51(9):753-62. PubMed ID: 23849325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.
    Grill S; Bruderer S; Sidharta PN; Antonova M; Globig S; Carlson J; Schultz A; Csonka D
    Br J Clin Pharmacol; 2020 Dec; 86(12):2424-2434. PubMed ID: 32374030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
    Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
    Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
    Lee J; Lee H; Jang K; Lim KS; Shin D; Yu KS
    Drug Des Devel Ther; 2014; 8():1781-8. PubMed ID: 25336921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects.
    Rhee SJ; Lee S; Yoon SH; Cho JY; Jang IJ; Yu KS
    Drug Des Devel Ther; 2016; 10():1411-8. PubMed ID: 27110098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
    Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
    Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects.
    Yerino GA; Feleder EC; Halabe EK; Diaz L; Sakson M; Iglesias M; Haddad T; Roldán E; Mondelo N
    Int J Clin Pharmacol Ther; 2022 Apr; 60(4):192-206. PubMed ID: 35103587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
    Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects.
    Oh M; Shin JG; Ahn S; Kim BH; Kim JY; Shin HJ; Shin HJ; Ghim JL
    Drug Des Devel Ther; 2019; 13():991-997. PubMed ID: 31114155
    [No Abstract]   [Full Text] [Related]  

  • 54. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
    Dawra VK; Liang Y; Wei H; Pelletier K; Shi H; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):50-61. PubMed ID: 31207178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects.
    Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components.
    Jeon I; Moon SJ; Park SI; Choi Y; Jung J; Yu KS; Chung JY
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):91-99. PubMed ID: 34159751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.
    Okour M; Puri A; Chen G; Port K; Berni A; Khindri S; Schneider I; Tenero D
    Clin Ther; 2019 Jun; 41(6):1110-1127. PubMed ID: 31060740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.